HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioDynamics co-founder to lead Delcath

This article was originally published in Clinica

Executive Summary

Liver cancer treatment specialist Delcath Systems has appointed Eamonn Hobbs president and CEO. Mr Hobbs will bring to the New York firm over 25 years' experience in interventional radiology, interventional cardiology and gastroenterology device industries. He co-founded AngioDynamics, where he was president and CEO until earlier this year. Mr Hobbs succeeds Richard Taney, who will continue to serve on Delcath's board of directors. The company is developing a system designed to deliver ultra-high doses of anti-cancer drugs to the liver, while preventing systemic side-effects associated with chemotherapy. It is currently enrolling patients in phase 2 and 3 clinical studies for treatment of liver cancers using melphalan.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel